Weight loss drug Wegovy sales fuel Novo Nordisk stock performance
Novo Nordisk (NVO) stock rose after the pharmaceutical company reported strong third-quarter sales growth, fueled by its popular weight-loss drug, Wegovy. The obesity treatment generated $1.7 billi...
Why Novo Nordisk Stock Is Surging Higher Today
Danish pharma titan Novo Nordisk released its latest financial report Thursday morning. For the first nine months of 2023, the company posted double-digit percentage sales growth over the prior-yea...
Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month
The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month, a senior executive said on Thursday.
US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO
Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company's weight loss medications will “be lowered somewhat” through the end of the year as the company plans to be “gradually e...
Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up
Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.
Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months.
Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic
Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of its hugely popular weight-loss drug Wegovy, a sen...
Novo Nordisk: obesity drugs priority over century-old focus on insulin
Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, continuing the Danish drugmaker's shift away from i...
Ozempic Sales Up 58% As Drugmaker Novo Nordisk Nets Record Profits
Revenue for the Danish company behind the booming GLP-1 injectable drugs is up 29% so far this year.
Novo Nordisk shares higher on bumper Wegovy boost
Shares in Europe's largest drugs company rose 1.6% in early trade boosted by the performance of its breakthrough weight loss drug Wegovy. Novo Nordisk (NYSE:NVO) said sales of obesity medication in...
Novo Nordisk flags continued restrictions on Wegovy supplies
Novo Nordisk on Thursday reported record sales and operating profits for the third quarter but flagged continued restrictions on supplies of its hugely popular Wegovy weight-loss drug.
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should You Buy Novo Nordisk (NVO) Ahead of Earnings?
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Novo Nordisk makes its weight-loss drug Wegovy
Novo Nordisk is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy.
Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?
Novo Nordisk just acquired a promising pharmaceutical asset for kidney disease. The candidate could also address hypertension, so the potential market could be huge.
Related Companies